The critical role of alpha-synuclein in Parkinson's disease represents a pivotal discovery.
Some progress has been made over recent years in identifying disease-modifying therapies …

Highly reproducible epidemiological evidence shows that type 2 diabetes (T2D) increases
the risk and rate of progression of Parkinson's disease (PD), and crucially, the repurposing …

Impairments in systematic and regional glucose metabolism exist in patients with
Parkinson's disease (PD) at every stage of the disease course, and such impairments are …

Diabetes and its complications, Alzheimer's disease (AD), and Parkinson's disease (PD) are
increasing gradually, reflecting a global threat vis‐à‐vis expressing the essentiality of a …

We are witnessing a considerable increase in the incidence of Parkinson's disease (PD),
which may be due to the general ageing of the population. While there is a plethora of …

Parkinson's disease (PD) is a neurodegenerative disease characterized by the progressive
loss of dopaminergic neurons in the nigrostriatal pathway. Although the exact mechanisms …

Parkinson's disease (PD) is the second most prevalent neurodegenerative movement
disorder worldwide, which is primarily characterized by motor impairments. Even though …

Glycotoxins include the group of advanced glycation end-products (AGEs) and their
precursors, most of them highly reactive intermediary compounds of sugar metabolism …

Advanced glycation end products (AGEs) arise from the Maillard reaction between
dicarbonyls and proteins, nucleic acids, or specific lipids. Notably, AGEs are linked to aging …

Pathologies characteristic of Alzheimer's disease (ie, hyperphosphorylated tau and amyloid-
β (Aβ) plaques), cardiovascular disease, and limbic predominant TDP-43 encephalopathy …